Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
FiercePharma16h
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
Piper Sandler Sticks to Its Buy Rating for Gilead Sciences (GILD)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
StockStory.org on MSN11h
Why Gilead Sciences (GILD) Stock Is Trading Up Today
What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session ...
Gilead price target raised to $100 from $95 at TD Cowen
TD Cowen raised the firm’s price target on Gilead (GILD) to $100 from $95 and keeps a Buy rating on the shares. The firm said they posted a ...